Holen Sie sich die Stockscreener-App
429.33
0.37%
1.57
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TMO?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$427.76
Offen:
$428.62
24-Stunden-Volumen:
1.36M
Relative Volume:
0.53
Marktkapitalisierung:
$156.49B
Einnahmen:
$42.90B
Nettoeinkommen (Verlust:
$6.52B
KGV:
25.18
EPS:
17.05
Netto-Cashflow:
$6.72B
1W Leistung:
+4.18%
1M Leistung:
+7.35%
6M Leistung:
-19.30%
1J Leistung:
-19.84%
1-Tages-Spanne:
$426.08
$432.90
1-Wochen-Bereich:
$401.45
$432.90
52-Wochen-Spanne:
$385.46
$627.88
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Firmenname
Thermo Fisher Scientific Inc
Sektor
Branche
Telefon
(781) 622-1000
Adresse
168 THIRD AVENUE, WALTHAM, MA
Vergleichen Sie TMO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
429.33 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
203.20 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
547.01 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
121.38 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
164.24 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-01 | Eingeleitet | Stephens | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-03-18 | Fortgesetzt | Citigroup | Neutral |
| 2024-01-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-26 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-06 | Fortgesetzt | Citigroup | Buy |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-07-19 | Bestätigt | Robert W. Baird | Outperform |
| 2023-07-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Bestätigt | Barclays | Overweight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-27 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Fortgesetzt | Barclays | Overweight |
| 2021-10-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-16 | Eingeleitet | The Benchmark Company | Buy |
| 2021-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-15 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Bestätigt | Needham | Buy |
| 2020-04-23 | Bestätigt | Needham | Buy |
| 2020-01-31 | Bestätigt | Needham | Buy |
| 2020-01-22 | Eingeleitet | Credit Suisse | Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-25 | Bestätigt | Needham | Buy |
| 2019-07-16 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2019-05-23 | Bestätigt | Needham | Strong Buy |
| 2019-04-22 | Bestätigt | Needham | Strong Buy |
| 2019-04-16 | Bestätigt | BofA/Merrill | Buy |
Alle ansehen
Thermo Fisher Scientific Inc Aktie (TMO) Neueste Nachrichten
Hyderabad-based CCMB, Thermo Fisher Scientific launch supply centre, aims at strengthening research in life sciences - Telangana Today
Thermo Fisher Scientific Inc. stock falls Tuesday, underperforms market - MSN
Thermo Fisher’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Thermo Fisher stock hits 52-week low at $390.45 - Investing.com
Thermo Fisher stock hits 52-week low at $390.45 By Investing.com - Investing.com South Africa
Thermo Fisher Scientific’s SWOT analysis: stock outlook amid acquisitions, tariffs - Investing.com
Thermo Fisher Scientific Unveils New Mass Spectrometers to Advance Scientific Discovery - Insider Monkey
Thermo Fisher Scientific introduces the next generation Thermo Scientific™ Vanquish™ Charged Aerosol Detector P Series for more sensitive detection of impurities - bio-itworld.com
Thermo Fisher Scientific (TMO) Opinions on Diagnostics Division Sale - Nasdaq
Thermo Fisher Scientific Could Divest Diagnostics Division for More than $4B - Medical Device and Diagnostic industry
Flow Cytometer | Thermo Fisher Scientific Inc. | Jun 2025 - Photonics Spectra
Thermo Fisher Scientific Awarded $94M Navy Occupational Dosimetry System Contract - ExecutiveBiz
Tufts Center Study Shows Significant Time Savings in Delivering Therapies to Patients with Thermo Fisher Scientific’s Accelerator™ Drug Development 360° CDMO and CRO Solutions - Business Wire
Ethris and Thermo Fisher partner on mRNA solutions - Yahoo Finance
Bioreactor Market Insights 2025-2033 | Leading Vendors: Thermo Fisher Scientific, GE Healthcare, Sartorius - openPR.com
Thermo Fisher (TMO) Eyes Future Growth with Strategic mRNA Deal and Acquisition - Daily Chhattisgarh News
Next-Gen Diagnostics Drive Biochips Market Growth: Thermo Fisher, Illumina, and PerkinElmer at the Forefront - openPR.com
Report: Biotech Research Firm Thermo Fisher Considers Selling Diagnostics Business - PYMNTS.com
Thermo Fisher Scientific Explores Diagnostics Exit Amid mRNA Expansion S&P 500 - Kalkine Media
Thermo Fisher Scientific (NYSE:TMO) Explores US$4 Billion Diagnostics Sale, Expands mRNA Collaboration - simplywall.st
Thermo Fisher Stock Hurt by Macroeconomic Woes, Tough Competition - MSN
Ethris and Thermo Fisher Partner to Streamline mRNA Therapeutics Development - BioPharm International
October 17th Options Now Available For Thermo Fisher Scientific (TMO) - Nasdaq
High Frequency Electrocautery Market Deep Research Report with - openPR.com
Deals of the day-Mergers and acquisitions - marketscreener.com
Ethris Signs Strategic Collaboration with Thermo Fisher Scientific to Provide Access to mRNA Technology Platforms - Business Wire
Thermo Fisher said to weigh sale of some diagnostic assets for $4B - MSN
Thermo Fisher (TMO) Plans $4 Billion Sale of Diagnostics Divisio - GuruFocus
Thermo Fisher (TMO) Considers $4B Sale of Diagnostic Assets - GuruFocus
Thermo Fisher Reportedly Plans to Sell Parts of Diagnostics Unit for $4 Billion - marketscreener.com
Thermo Fisher plans to sell parts of diagnostics unit for $4 billion, FT reports - ET HealthWorld
Thermo Fisher plans to sell parts of diagnostics unit for $4 billion, FT reports By Reuters - Investing.com
Thermo Fisher Plans to Sell Parts of Diagnostics Unit for $4 Billion, FT Reports - US News Money
Thermo Fisher aims to sell parts of its diagnostics business for $4 billion, FT reports - TradingView
Thermo Fisher aims to sell parts of its diagnostics business for $4bn - Financial Times
Thermo Fisher (TMO) Stock Shows Signs of Rebound After Challenging Year - Daily Chhattisgarh News
Plasmid Purification Market Exclusive Report with Detailed - openPR.com
Regeneron Genetics Center Selects Olink® Explore HT for Landmark Proteomics Study of 200,000 Patient Samples - Business Wire
APJ, EEMEA and LATAM Thermo Scientific AST plate guide - SelectScience
Brain Cancer Diagnostics Market Key Players AnalysisThermo - openPR.com
Molecular Diagnostics for Cancer Market Research 2025: Advances in Personalized Medicine and Liquid Biopsies Reshape Industry Landscape - GlobeNewswire Inc.
Thermo Fisher (TMO) Closes with Minor Gains After Volatile Session, Stock Still Down Significantly for the Year - Daily Chhattisgarh News
Ex-Dividend Reminder: Gilead Sciences, CONMED and Thermo Fisher Scientific - Nasdaq
HSBC Adjusts Price Target on Thermo Fisher Scientific to $560 From $590 - marketscreener.com
Thermo Fisher Scientific highlights case for combining electron microscopy and microtomography - Metal Additive Manufacturing magazine
Thermo Fisher (TMO) Rallies Over 1%, But Still Faces Long-Term Headwinds - Daily Chhattisgarh News
$100 Invested In Thermo Fisher Scientific 20 Years Ago Would Be Worth This Much Today - Benzinga
Thermo Scientific Precis Methods - SelectScience
Thermo Scientific SureTect automation workflow - SelectScience
Thermo Fisher Cuts Annual Profit Outlook Amid Estimated $400M Tariff Hit - insights.citeline.com
Old National Bancorp Reduces Stake in Thermo Fisher Scientific - Zenopa
Finanzdaten der Thermo Fisher Scientific Inc-Aktie (TMO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.35%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):